Category: News

BOULDER, Colo. Biodesix, Inc. has announced its intent to extend the company’s blood-based lung cancer diagnostic portfolio with acquisition of Oncimmune Holdings Group’s laboratory and incidental pulmonary nodule (IPN) malignancy test in the United States. The United Kingdom-based company’s U.S. operations, including a CLIA lab in De Soto, Kansas, will transition to Biodesix on November…

Biodesix, Boulder, Colo- based company is extending its blood-based lung cancer diagnostic portfolio with the acquisition of Oncimmune’s laboratory and incidental pulmonary nodule malignancy test in the U.S.

Immodulon to utilize biomarkers identified by Biodesix’ machine learning platform, aiming to accelerate the clinical development of its pancreatic treatment.

Biodesix, Boulder, Colo, and Immodulon have announced a joint venture into biomarker research. The partnership will focus on the analysis of the circulating proteome of advanced pancreatic cancer patients treated with IMM-101 using the Biodesix Diagnostic Cortex machine learning platform.

Biodesix, Boulder, Colo, has recently presented new data demonstrating that the company’s VeriStrat test is predictive of outcomes for patients with non-small cell lung cancer (NSCLC) treated with immune checkpoint inhibitors in the frontline setting, even when adjusted for PD-L1 status.1,2

A New Collaboration Could Be Key in the Early Detection of Lung Cancer

Biodesix, MRM Proteomics Partner on Blood-Based Lung Cancer Diagnosticsby Alex Philippidis

Biodesix Partners with MRM for mass spec proteomics development

Biodesix’s primary immunotherapy resistance test demonstrated utility in classifying NSCLC patients treated with nivolumab by overall survival. The test classification is independent of PD-L1 status.   “Anti-PD-1 therapy is capable of restoring immunity and has greatly increased overall survival rates for patients. However, we know that this therapy does not benefit everyone,” says Egbert Smit,…